220060-39-9

220060-39-9 structure

Name: Thioquinapiperifil
Chemical Name: 3-ethyl-8-[[2-[4-(hydroxymethyl)piperidin-1-yl]phenyl]methylamino]-1H-imidazo[4,5-g]quinazoline-2-thione
CAS Number: 220060-39-9
Molecular Formula: C₂₄H₂₈N₆OS
Molecular Weight: 448.58400
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
Create Date: 2017-07-13 10:13:56
Modify Date: 2024-01-09 20:44:04
Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive phosphodiesterase-5 (PDE-5, IC50 of 0.074 nM) inhibitor, is used for sexual enhancement study[1][2].

Name	3-ethyl-8-[[2-[4-(hydroxymethyl)piperidin-1-yl]phenyl]methylamino]-1H-imidazo[4,5-g]quinazoline-2-thione

Description	Thioquinapiperifil (KF31327 free base), a potent, selective and non-competitive phosphodiesterase-5 (PDE-5, IC50 of 0.074 nM) inhibitor, is used for sexual enhancement study[1][2].
Related Catalog	Research Areas >> Endocrinology Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Metabolic Disease
Target	PDE5:0.074 nM (IC50) PDE1:380 nM (IC50) PDE2:670 nM (IC50) PDE3:38 nM (IC50) PDE4:800 nM (IC50)
In Vitro	Thioquinapiperifil can be found in dietary supplements[1]. Thioquinapiperifil (KF31327 free base) (0.1-10 μM) concentration dependently inhibits platelet aggregation. In the absence of nitroglycerin, higher concentrations 1 and 10 μM of Thioquinapiperifil (KF31327 free base) are required to inhibit platelet aggregation[2]. Thioquinapiperifil (KF31327 free base) and shows significant increase in cyclic GMP at 10 μM. After 5 min incubation, the mean cyclic GMP levels of Thioquinapiperifil (KF31327)-treated cells is 0.95±0.17 pmol/108 cells[2].
References	[1]. Nahoko Uchiyama, et al. Determination of a new type of phosphodiesterase-5 inhibitor, thioquinapiperifil, in a dietary supplement promoted for sexual enhancement. Chem Pharm Bull (Tokyo). 2008 Sep;56(9):1331-4. [2]. R Hirose, et al. KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. Eur J Pharmacol. 2001 Nov 9;431(1):17-24.